Business Context and Reporting Period
This Form 8-K filing by Pacific Biosciences of California, Inc. reports on events occurring between February 13, 2018, and February 20, 2018. The filing details the full exercise of an underwriters' option to purchase additional shares of common stock following a public offering.
Key Financial Metrics
- Shares Issued: 1,875,000 shares of Common Stock (Option Shares).
- Offering Price: $2.40 per share.
- Net Proceeds: Approximately $4.3 million after deducting underwriting discounts and estimated offering expenses.
- Closing Date: February 20, 2018.
Material Changes
The primary material change is the increase in the Company's equity capitalization and cash liquidity resulting from the sale of the Option Shares. This transaction was executed pursuant to an underwriting agreement dated February 13, 2018, with Cantor Fitzgerald & Co. as the representative underwriter. The filing text does not provide comparative financial metrics (revenue, profit, or margins) for prior periods as this is a current report on a specific capital event rather than a periodic financial statement.
Outlook, Risks, and Unusual Items
The filing does not contain management commentary on future guidance, operational outlook, or specific risk factors beyond the standard disclosures associated with the equity offering. The transaction was conducted under a shelf registration statement (Form S-3) declared effective on August 18, 2017. No unusual items or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the final net proceeds received by the Company after all transaction costs.
- Confirm the updated total share count and dilution impact on existing shareholders.
- Review the full Underwriting Agreement for details on lock-up periods or other covenants.
- Check subsequent filings for the actual use of the $4.3 million in proceeds.